Last $8.87 USD
Change Today +0.10 / 1.14%
Volume 477.2K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Key Developments

Halozyme To Explore Strategic Alternatives

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) intends to explore partnerships and/or strategic alternatives for the Hylenex program in diabetes.

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Halozyme Therapeutics, Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $14,606,000 compared to total revenues of $16,013,000 for the same period a year ago. Operating loss was $19,026,000 compared to $18,494,000 last year. Net loss was $20,280,000 or $0.16 per basic and diluted share compared to $19,292,000 or $0.17 per basic and diluted share last year. For the nine months, the company reported total revenues of $44,957,000 compared to total revenues of $42,301,000 for the same period a year ago. Operating loss was $59,185,000 compared to $59,110,000 last year. Net loss was $63,101,000 or $0.52 per basic and diluted share compared to $61,492,000 or $0.55 per basic and diluted share last year.

Halozyme Therapeutics Inc. Reduces Workforce for Corporate Reorganization

Halozyme Therapeutics, Inc. announced that it completed a corporate reorganization to align with strategic priorities, resulting in a workforce reduction 13% or 22 employees.

Halozyme Therapeutics, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Halozyme Therapeutics, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 10, 2014

Halozyme Therapeutics, Inc., Q3 2014 Earnings Call, Nov 10, 2014

Halozyme Therapeutics, Inc., Q3 2014 Earnings Call, Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $8.87 USD +0.10

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $10.61 USD -0.01
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.9x
Price/Book 27.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.